Interventions for treatment of COVID-19: A protocol for a living systematic review with network meta-analysis including individual patient data (The LIVING Project)

Research output: Contribution to journalReview article

Standard

Interventions for treatment of COVID-19 : A protocol for a living systematic review with network meta-analysis including individual patient data (The LIVING Project). / Juul, Sophie; Nielsen, Niklas; Bentzer, Peter; Veroniki, Areti Angeliki; Thabane, Lehana; Linder, Adam; Klingenberg, Sarah; Gluud, Christian; Jakobsen, Janus Christian.

In: Systematic Reviews, Vol. 9, No. 1, 108, 09.05.2020.

Research output: Contribution to journalReview article

Harvard

APA

CBE

MLA

Vancouver

Author

Juul, Sophie ; Nielsen, Niklas ; Bentzer, Peter ; Veroniki, Areti Angeliki ; Thabane, Lehana ; Linder, Adam ; Klingenberg, Sarah ; Gluud, Christian ; Jakobsen, Janus Christian. / Interventions for treatment of COVID-19 : A protocol for a living systematic review with network meta-analysis including individual patient data (The LIVING Project). In: Systematic Reviews. 2020 ; Vol. 9, No. 1.

RIS

TY - JOUR

T1 - Interventions for treatment of COVID-19

T2 - A protocol for a living systematic review with network meta-analysis including individual patient data (The LIVING Project)

AU - Juul, Sophie

AU - Nielsen, Niklas

AU - Bentzer, Peter

AU - Veroniki, Areti Angeliki

AU - Thabane, Lehana

AU - Linder, Adam

AU - Klingenberg, Sarah

AU - Gluud, Christian

AU - Jakobsen, Janus Christian

PY - 2020/5/9

Y1 - 2020/5/9

N2 - Background: COVID-19 is a rapidly spreading virus infection that has quickly caused extensive burden to individual, families, countries, and the globe. No intervention has yet been proven effective for the treatment of COVID-19. Some randomized clinical trials assessing the effects of different drugs have been published, and more are currently underway. There is an urgent need for a living, dynamic systematic review that continuously evaluates the beneficial and harmful effects of all available interventions for COVID-19. Methods/design: We will conduct a living systematic review based on searches of major medical databases (e.g., MEDLINE, EMBASE, CENTRAL) and clinical trial registries from their inception onwards to identify relevant randomized clinical trials. We will update the literature search once a week to continuously assess if new evidence is available. Two review authors will independently extract data and perform risk of bias assessment. We will include randomized clinical trials comparing any intervention for the treatment of COVID-19 (e.g., pharmacological interventions, fluid therapy, invasive or noninvasive ventilation, or similar interventions) with any comparator (e.g., an "active" comparator, standard care, placebo, no intervention, or "active placebo") for participants in all age groups with a diagnosis of COVID-19. Primary outcomes will be all-cause mortality and serious adverse events. Secondary outcomes will be admission to intensive care, mechanical ventilation, renal replacement therapy, quality of life, and non-serious adverse events. The living systematic review will include aggregate data meta-analyses, Trial Sequential Analyses, network meta-analysis, and individual patient data meta-analyses. Risk of bias will be assessed with domains, an eight-step procedure will be used to assess if the thresholds for clinical significance are crossed, and the certainty of the evidence will be assessed by Grading of Recommendations, Assessment, Development and Evaluations (GRADE). Discussion: COVID-19 has become a pandemic with substantial mortality. A living systematic review evaluating the beneficial and harmful effects of pharmacological and other interventions is urgently needed. This review will continuously inform best practice in treatment and clinical research of this highly prevalent disease. 

AB - Background: COVID-19 is a rapidly spreading virus infection that has quickly caused extensive burden to individual, families, countries, and the globe. No intervention has yet been proven effective for the treatment of COVID-19. Some randomized clinical trials assessing the effects of different drugs have been published, and more are currently underway. There is an urgent need for a living, dynamic systematic review that continuously evaluates the beneficial and harmful effects of all available interventions for COVID-19. Methods/design: We will conduct a living systematic review based on searches of major medical databases (e.g., MEDLINE, EMBASE, CENTRAL) and clinical trial registries from their inception onwards to identify relevant randomized clinical trials. We will update the literature search once a week to continuously assess if new evidence is available. Two review authors will independently extract data and perform risk of bias assessment. We will include randomized clinical trials comparing any intervention for the treatment of COVID-19 (e.g., pharmacological interventions, fluid therapy, invasive or noninvasive ventilation, or similar interventions) with any comparator (e.g., an "active" comparator, standard care, placebo, no intervention, or "active placebo") for participants in all age groups with a diagnosis of COVID-19. Primary outcomes will be all-cause mortality and serious adverse events. Secondary outcomes will be admission to intensive care, mechanical ventilation, renal replacement therapy, quality of life, and non-serious adverse events. The living systematic review will include aggregate data meta-analyses, Trial Sequential Analyses, network meta-analysis, and individual patient data meta-analyses. Risk of bias will be assessed with domains, an eight-step procedure will be used to assess if the thresholds for clinical significance are crossed, and the certainty of the evidence will be assessed by Grading of Recommendations, Assessment, Development and Evaluations (GRADE). Discussion: COVID-19 has become a pandemic with substantial mortality. A living systematic review evaluating the beneficial and harmful effects of pharmacological and other interventions is urgently needed. This review will continuously inform best practice in treatment and clinical research of this highly prevalent disease. 

KW - COVID-19

KW - Covid-19

UR - http://www.scopus.com/inward/record.url?scp=85084405749&partnerID=8YFLogxK

U2 - 10.1186/s13643-020-01371-0

DO - 10.1186/s13643-020-01371-0

M3 - Review article

C2 - 32386514

AN - SCOPUS:85084405749

VL - 9

JO - Systematic Reviews

JF - Systematic Reviews

SN - 2046-4053

IS - 1

M1 - 108

ER -